NYXOAH SA
| General Information | |
| Business: | (Note: IPOScoop has No Call on this offering because this is NOT a traditional IPO. This is an uplift of ordinary shares to the NASDAQ. The company’s shares already trade on the Euronext Brussels.)
We are a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, or OSA. Our lead solution is the Genio system, a CE-Marked, patient-centric minimally invasive next- generation hypoglossal neurostimulation therapy for the treatment of moderate to severe OSA. The Genio system includes a single implanted device that can be placed through a minimally invasive single-incision surgery under the chin. We began selling the Genio system in Europe in July 2020.
Our Genio system is an alternative to the continuous positive airway pressure, or CPAP system. The CPAP system is a standard of care first-line treatment for OSA whereby air, at a constant or automated pressure, is pushed into the upper airway via a facial or nasal mask that the patient must wear during sleep. Despite its proven efficacy, CPAP has been associated with many limitations that make compliance a serious challenge.
*Financial figures are reported in euros. For 2020, the company reported revenues of 69,000 euros and a net loss of 12.245 euros.
(Note: Nyxoah SA priced its NASDAQ uplift offering of 2.835 million ordinary shares on July 1, 2021, at US$30 – below the projected price of US$31.46, based on the stock’s recent close on the Euronext Brussels – to raise $85.1 million. Insiders – existing shareholders Cochlear Investments Pty. Ltd. and ResMed, Inc., indicated an interest in buying an aggregate of up to $34 million of stock in the IPO, the prospectus says.)
|
| Industry: | Medical Devices |
| Employees: | 78 |
| Founded: | 2009 |
| Contact Information | |
| Address | Rue Edouard Belin 12 1435 Mont-Saint-Guibert, Belgium |
| Phone Number | +32 10 22 23 55 |
| Web Address | http://www.nyxoah.com/ |
| View Prospectus: | NYXOAH SA |
| Financial Information | |
| Market Cap | $782.41mil |
| Revenues | $0.07 mil (last 12 months) |
| Net Income | $-12.25 mil (last 12 months) |
| IPO Profile | |
| Symbol | NYXH |
| Exchange | NASDAQ |
| Shares (millions): | 2.8 |
| Price range | $30.00 - $30.00 |
| Est. $ Volume | $85.1 mil |
| Manager / Joint Managers | Piper Sandler/ Stifel/ Cantor Fitzgerald |
| CO-Managers | Degroof Petercam |
| Expected To Trade: | 7/2/2021 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |